Novo Nordisk reported strong data for its next-gen anti-obesity medicine. The Danish company has an excellent weight loss drug pipeline. But it's also diversifying its lineup and offering other ...

That haul helped Novo’s total sales for 2024 grow 26% at constant currencies to 290.4 billion kroner (nearly $41 billion), contributing to operating profits of 128.3 billion kroner ($18 billion ...

Milan Vidojevic as Director of Quantitative Solutions, International in January 2024; and Jan Rohof as Director of Quantitative Solutions, Asia Pacific in November 2024. NTAM manages US$43 billion ...

Marcus Rashford said he was ready for a "new challenge" ahead of the January transfer window; AC Milan and Borussia Dortmund have been among the interested parties; Milan are only allowed to sign ...

Thankfully, the stylish fellas at Milan Fashion Week—which kicked off this weekend—are pros at layering up in style. On the first day of the men’s Fall-Winter 2025 runway shows, our eagle ...

LISBON, Jan 31 (Reuters) - U.S. private equity firm Lone Star has told the Portuguese government that it is likely to sell a 25-30% stake in Novo Banco via an initial public offering, rather than ...

Thiago Motta's Juventus will host AC Milan on Saturday for one of the most awaited matchups of the season, two weeks after the Rossoneri managed to make a comeback against them and win the ...

The latest menswear shows in Milan for the Fall-Winter 2025 season left their usual buoyant mood at the door. Instead, the focus was two-fold: timeless style featuring classic fabrics like ...

Novo Nordisk is facing serious pressure from a powerful adversary. It still has plenty of leeway to penetrate its target market, for now. Investors should keep a close eye on this company. But it ...

Novo Nordisk (NVO) announced Friday that its popular obesity therapy, semaglutide, marketed as Wegovy, led to 20.7% weight loss over 72 weeks at a higher dose of 7.2 mg in a late-stage trial ...

(Reuters) -The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with ...

Novo Nordisk (NVO) ended the recent trading session at $84.62, demonstrating a -1.9% swing from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.16%. At the same ...